Skip to main content
. 2016 Jul 8;8(9):992–1004. doi: 10.15252/emmm.201606370

Figure 5. Compensation of reduced amyloid plaque clearance by elevated antibody dose.

Figure 5

  1. Cryosections from unfixed brain of 6‐month‐old APP/PS1 mice were pre‐incubated with increasing concentrations of mAb11 (0.001, 0.01, 0.1, 1, 5 μg/ml). BMDM from wt or Trem2 ko mice were added for 24 h. Sections were stained with methoxy‐X04. Scale bar, 500 μm.
  2. Methoxy‐X04 signals were quantified from the entire sagittal section. (n = 5, ± SEM; two‐way ANOVA, interaction P = 0.0082, genotype P < 0.0001, treatment P < 0.0001. Fisher's LSD post hoc comparisons; * show statistics between wt and ko under the same experimental condition. # in black shows wt compares to no‐antibody stimulation; # in gray shows ko compares to no‐antibody stimulation; wt vs. ko for the following conditions: no antibody P = 0.0053, mAb11 0.001 μg/ml P = 0.0003, mAb11 0.01 μg/ml P < 0.0001, mAb11 0.1 μg/ml P = 0.0001, mAb11 1 μg/ml P = 0.0007, mAb11 5 μg/ml P = 0.0011; following conditions compare to wt/no antibody: wt/mAb11 0.01 μg/ml P = 0.0166, wt/mAb11 0.1 μg/ml P = 0.0002, wt/mAb11 1 μg/ml P < 0.0001, wt/mAb11 5 μg/ml P < 0.0001; following conditions compare to ko/no antibody: ko/mAb11 0.1 μg/ml P = 0.0099, ko/mAb11 1 μg/ml P < 0.0001, ko/mAb11 5 μg/ml P < 0.0001.